GlassScriptPhysician profile
Ricardo Abreu
NPI 1265469803
$4,860.16
in general payments reported to CMS, 2019-2025
17 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,361 · 2020: $12.70 · 2021: $41.70 · 2022: $790 · 2023: $1,366 · 2024: $217 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594 · Travel and Lodging: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.78 |
| Travel and Lodging | $1,061.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $3,219.41 | 2019-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Stryker Corporation | $594.47 | 2024-2025 | Flexband, Aequalis Perform, Alphavent |
| Medtronic, INC. | $242.04 | 2022-2025 | Illumisite |
| United Therapeutics Corporation | $122.79 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.39 | 2025 | |
| Itamar Medical INC | $109.08 | 2024-2025 | Watchpatone |
| Galvanize Therapeutics, INC | $91.06 | 2025 | Aliya System |
| Fisher & Paykel Healthcare INC | $71.35 | 2025 | Fisher & Paykel Healthcare |
| Glaxosmithkline, LLC. | $67.01 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Boston Scientific Corporation | $40.77 | 2022 | |
| Inogen, INC. | $40.55 | 2023 | Inogen |
| Astrazeneca Pharmaceuticals LP | $30.91 | 2021-2022 | |
| Vyaire Medical, INC. | $30.14 | 2021 | |
| Grifols USA, LLC | $26.35 | 2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $24.73 | 2024 | Aralast |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20.41 | 2019 | |
| Merck Sharp & Dohme LLC | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Abreu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.